Published in J Med Virol on September 01, 1987
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc Natl Acad Sci U S A (1991) 1.34
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol (1990) 1.13
Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci U S A (1991) 1.08
Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides. J Clin Microbiol (1993) 0.99
Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides. Immunology (1989) 0.95
Vaccination against lethal coronavirus-induced encephalitis with a synthetic decapeptide homologous to a domain in the predicted peplomer stalk. J Virol (1988) 0.88
New sensitive and specific assay for human immunodeficiency virus antibodies using labeled recombinant fusion protein and time-resolved fluoroimmunoassay. J Clin Microbiol (1990) 0.87
Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. J Virol (2012) 0.86
Oligopeptide-based enzyme immunoassay for ovine lentivirus antibody detection. J Clin Microbiol (1994) 0.85
Analysis of a subclass-restricted HIV-1 gp41 epitope by omission peptides. Immunology (1989) 0.81
Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India. PLoS One (2012) 0.80
Differential diagnosis of human retrovirus infections in the laboratory. Yale J Biol Med (1989) 0.75
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol (1990) 5.64
A new classification for HIV-1. Nature (1998) 5.30
Two distinct subtypes of human respiratory syncytial virus. J Gen Virol (1985) 5.19
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
The regulation of pinocytosis in mouse macrophages. II. Factors inducing vesicle formation. J Exp Med (1967) 4.17
Ultrastructural features of Mycoplasma pneumoniae. J Bacteriol (1970) 3.84
Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet (1993) 3.72
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (1999) 3.51
Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
HIV counseling and testing of pregnant women in sub-Saharan Africa: experiences from a study on prevention of mother-to-child HIV-1 transmission in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr (2001) 2.81
Presence of haemagglutinin in the envelope of extracellular vaccinia virus particles. J Gen Virol (1976) 2.78
Antibodies to brain and other tissues in cases of Mycoplasma pneumoniae infection. Clin Exp Immunol (1971) 2.76
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76
Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol (1990) 2.71
Antibody response in primary human immunodeficiency virus infection. Lancet (1987) 2.69
Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques (1993) 2.65
Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS (1997) 2.60
Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry (2001) 2.59
Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. Proc Natl Acad Sci U S A (1996) 2.57
Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA (1999) 2.56
Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis (1975) 2.54
Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci U S A (1993) 2.49
Tempo and mode of nucleotide substitutions in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history. J Virol (1997) 2.47
Respiratory syncytial virus envelope glycoprotein (G) has a novel structure. Nucleic Acids Res (1985) 2.37
Codistribution of collagen types IV and AB2 in basement membranes and mesangium of the kidney. an immunoferritin study of ultrathin frozen sections. J Cell Biol (1980) 2.30
Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses (1991) 2.29
The regulation of pinocytosis in mouse macrophages. IV. The immunological induction of pinocytic vesicles, secondary lysosomes, and hydrolytic enzymes. J Exp Med (1967) 2.29
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28
Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol (1976) 2.24
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A (1998) 2.23
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
The structural and functional diversity of Adenovirus capsid components. J Gen Virol (1969) 2.14
The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc Natl Acad Sci U S A (1999) 2.11
Structural polypeptides of measles virus. J Gen Virol (1978) 2.11
Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology (1987) 2.11
Oligoclonal IgG antibody response in the central nervous system to different measles virus antigens in subacute sclerosing panencephalitis. Proc Natl Acad Sci U S A (1973) 2.10
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08
Appearance and persistence of antibodies against different virus components after regular measles infections. Infect Immun (1972) 2.08
Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. Virology (1995) 2.07
Adsorption and penetration of enveloped and naked vaccinia virus particles. J Virol (1978) 2.06
Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol (1987) 2.06
Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J Virol (1991) 2.05
Intuitive hypertext-based molecular identification of micro-organisms. Lancet (1999) 2.01
Infection of brain-derived cells with the human immunodeficiency virus. J Virol (1987) 2.01
Identification of measles virus-specific hemolysis-inihibiting antibodies separate from hemagglutination-inhibiting antibodies. Infect Immun (1975) 2.01
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet (2000) 1.94
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 1.93
Characterization of Chlamydia trachomatis omp1 genotypes among sexually transmitted disease patients in Sweden. J Clin Microbiol (2001) 1.90
HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol (1986) 1.88
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis (1993) 1.86
Monoclonal antibodies against five structural components of measles virus. I. Characterization of antigenic determinants on nine strains of measles virus. Virology (1983) 1.85
Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS (1989) 1.83
Mycoplasma pneumoniae is a polyclonal B-cell activator. Nature (1976) 1.83
Identification of different measles virus-specific antibodies in the serum and cerebrospinal fluid from patients with subacute sclerosing pancencephalitis and multiple sclerosis. Infect Immun (1972) 1.82
Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden. J Med Virol (1986) 1.81
Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol (2001) 1.79
Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm. Virology (1991) 1.77
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults. J Clin Microbiol (1997) 1.76
Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS (2000) 1.75
Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ (1988) 1.75
Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B. J Gen Virol (1987) 1.73
Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol (1994) 1.72
Target-effector interaction in the natural killer cell system: isolation of target structures. Proc Natl Acad Sci U S A (1979) 1.71
Monitoring of HIV-1 infection prevalence and trends in the general population using pregnant women as a sentinel population: 9 years experience from the Kagera region of Tanzania. J Acquir Immune Defic Syndr (2000) 1.70
Respiratory syncytial virus fusion glycoprotein: nucleotide sequence of mRNA, identification of cleavage activation site and amino acid sequence of N-terminus of F1 subunit. Nucleic Acids Res (1985) 1.69
Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses (1999) 1.69
A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res Hum Retroviruses (1987) 1.67